Merck Remains Active In Pursuit Of Mevacor Rx-to-OTC Switch In U.S.
This article was originally published in The Tan Sheet
Executive Summary
Merck continues to work with FDA over a possible switch of Mevacor (lovastatin) to over-the-counter status in the U.S. this year
You may also be interested in...
Zocor UK Switch Decision Could Be Moved Up
The British Department of Health could decide to switch Merck's Zocor (simvastatin) to behind-the-counter status in the UK by late March
Will Pravachol Follow Zocor On UK Switch Route?
Mounting pressure on Pravachol revenues in 2004 due to the loss of patent exclusivity in Europe and an increasingly competitive U.S. landscape could prompt Bristol-Myers Squibb to intensify efforts to gain nonprescription status for the drug in both markets
Mevacor Study Comparing Rx, OTC Use Is Among FDA Panel Suggestions
Merck should conduct a head-to-head comparison study of Mevacor use in prescription and over-the-counter settings, Endocrinologic & Metabolic Drugs Advisory Committee member William Tamborlane, MD, said during a review of Merck's OTC switch application for lovastatin 10 mg.